Related Experiment Video

Updated: Jul 10, 2026

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

[Is it justifiable to administrate vitamin A, E and D for 6 months in the premature infants?]

B-L Salle1, E Delvin, O Claris

  • 1Service de réanimation et de néonatologie, hôpital Edouard-Herriot, université Claude-Bernard, place d'Arsonval, 69437 Lyon cedex 03, France. bernardsalle@orange.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|October 30, 2007
PubMed

Insights

Preterm infants have low vitamin A and E levels. Increasing vitamin A to 5000 IU/day for the first month, then 3000 IU for 5 months, is recommended for optimal nutritional status.

Area of Science:

  • Neonatal nutrition
  • Pediatric biochemistry
  • Vitamin metabolism

Context:

  • Limited data exists on vitamin A and E status in preterm infants.
  • Preterm infants (32-34 weeks gestation) often have suboptimal nutrient levels at birth.
  • Understanding vitamin supplementation effects is crucial for infant development.

Purpose:

  • To assess vitamin A, E, D, and retinol-binding protein (RBP) plasma concentrations in preterm infants.
  • To evaluate the impact of oral vitamin supplementation on these levels over 6 months.
  • To determine optimal vitamin A, E, and D dosages for preterm infants.

Summary:

  • At birth, preterm infants showed low plasma concentrations of vitamins A, E, D, and RBP.
  • Supplementation increased vitamin levels, but vitamin A did not reach normal values in term infants within 6 months.
  • Vitamin D levels normalized by 6 months, while vitamin E sufficiency was noted with the study dose.

Impact:

  • Suggests increasing vitamin A supplementation to 5000 IU/day for the first month, followed by 3000 IU/day for 5 months.
  • Recommends continuing current vitamin E and D doses for 6 months.
  • Highlights the need for adjusted vitamin A supplementation protocols in preterm infants for improved long-term nutritional status.
Abstract

More Related Videos

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Vitamins01:30

Vitamins

Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced in our...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...